Investors, partners and newsroom

CUTISS describes itself as the only late-stage clinical TechBio company developing skin tissue therapeutics and dedicated to bioengineering.

Automated, on-demand production

CUTISS has developed a patented, fully closed, end-to-end system for the scalable production of personalised tissue therapy, designed for decentralised production and cost-effective scale-up.

The same platform is intended to reach further: next-priority tissues such as gums, cornea and muscle, health research and industrial applications of bioengineered tissue.

  • Partnership with Tecan to industrialise the automated tissue platform. Wyss Zurich
  • Series C financing of CHF 56 million. tech.eu
  • U.S. patent for automated skin graft production methods. Press release
  • Dr. Achim von Leoprechting elected Chairman of the Board. Press release
  • Selected for EIC Accelerator support, project denovoProd. European Innovation Council
Portrait of Daniela Marino

Leadership

“Our product is an advanced therapy, and now we need Phase-3 data before we can proceed.”Daniela Marino, co-founder and CEO, in UZH News, January 2026. EY Entrepreneur Of The Year 2026.

Contact investor relations